Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review

Agustín Ciapponi a,⇑, Ariel Bardach a, Agustina Mazzoni a, Tomás Alconada a, Steven A. Anderson b, Fernando J. Argento a, Jamile Ballivian a, Karin Bok c, Daniel Comandé a, Emily Erbelding d, Erin Goucher e, Beate Kampmann f,g, Ruth Karron h, Flor M. Munoz i, María Carolina Palermo a, Edward P.K. Parker f, Federico Rodriguez Cairoli a, Victoria Santa María a, Andy S. Stergachis j, Gerald Voss k, Xu Xiong e, Natalia Zamora a, Sabra Zaraa l, Mabel Berrueta a, Pierre M. Buekens e

a Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina
b US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
c National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Dr # 7A03, Bethesda, MD 20892, USA
d National Institute of Allergy and Infectious Diseases, 31 Center Dr # 7A03, Bethesda, USA
e School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, New Orleans, LA 70112, USA
f The Vaccine Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
g Vaccines & Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia
h Bloomberg School of Public Health, Johns Hopkins University, 7CX5+8W Baltimore, MD, USA
i Baylor College of Medicine, Texas Children’s Hospital, 6621 Fannin St, Houston, TX 77030, USA
j School of Pharmacy and School of Public Health, University of Washington, MM2R+78 Seattle, WA, USA
k TuBerculosis Vaccine Initiative (TBVI), GHF4+6W Lelystad, the Netherlands
l School of Pharmacy, University of Washington, MM2R+78 Seattle, WA, USA

Article history:
Received 5 June 2021
Received in revised form 5 August 2021
Accepted 10 August 2021
Available online 13 August 2021

Keywords:
Pregnancy
COVID-19
Vaccine safety
Adjuvant
Systematic review

ABSTRACT

Background: Rapid assessment of COVID-19 vaccine safety during pregnancy is urgently needed.
Methods: We conducted a rapid systematic review, to evaluate the safety of COVID-19 vaccines selected by the COVID-19 Vaccines Global Access-Maternal Immunization Working Group in August 2020, including their components and their technological platforms used in other vaccines for pregnant persons. We searched literature databases, COVID-19 vaccine pregnancy registries, and explored reference lists from the inception date to February 2021 without language restriction. Pairs of reviewers independently selected studies through COVIDENCE, and performed the data extraction and the risk of bias assessment. Discrepancies were resolved by consensus. Registered on PROSPERO (CRD42021234185).
Results: We retrieved 6757 records and 12 COVID-19 pregnancy registries from the search strategy; 38 clinical and non-clinical studies (involving 2,398,855 pregnant persons and 56 pregnant animals) were included. Most studies (89%) were conducted in high-income countries and were cohort studies (57%). Most studies (76%) compared vaccine exposures with no exposure during the three trimesters of pregnancy. The most frequent exposure was to AS03 adjuvant, in the context of A/H1N1 pandemic influenza vaccines, (n = 24) and aluminum-based adjuvants (n = 11). Only one study reported exposure to messenger RNA in lipid nanoparticles COVID-19 vaccines. Except for one preliminary report about A/H1N1 influenza vaccination (adjuvant AS03), corrected by the authors in a more thorough analysis, all studies concluded that there were no safety concerns.
1. Background

The COVID-19 Vaccines Global Access Facility (COVAX) is a multilateral initiative to ensure that all countries have fair and equitable access to Coronavirus Disease 2019 (COVID-19) vaccines. Co-led by the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization), the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), COVAX is a voluntary arrangement that enables countries to pool their resources and risk by collectively investing in vaccine candidates while developing the political and logistical infrastructure needed for vaccine distribution in a transparent and coordinated manner [1–3]. Preauthorization clinical trials of COVID-19 vaccines excluded pregnant persons, and only limited human data on their safety during pregnancy was available at the time of emergency use authorization [4]. However, pregnant persons with COVID-19 are at increased risk of adverse pregnancy and birth outcomes and severe illness compared to non-pregnant persons [5–9]. Many countries are vaccinating or considering vaccinating pregnant persons, especially if they are at risk of being exposed, even with limited available data about the safety of this strategy. Consequently, it is imperative to identify early safety concerns of COVID-19 vaccines, their components, or their platforms, defined as any underlying technology -a mechanism, delivery method, or cell line- that can be used to develop multiple vaccines: whole virus, protein, viral vector, or nucleic acid. To assist pregnant persons to make more fully informed decisions, we aimed to identify safety concerns during pregnancy associated with these exposures over a subset of COVID-19 vaccines selected for review by COVAX-MIWG in August 2020, through a rapid review of the literature databases as the first phase of an ongoing full systematic review. Given the urgency of the issue for current public health practice across the globe, we performed a rapid review as an interim analysis of the vaccines that the COVAX-MIWG selected in August 2020.

2. Objectives

To evaluate the effects of COVID-19 vaccines that the COVAX-MIWG selected in August 2020, or their components used in other vaccines, on pregnancy safety outcomes.

3. Methods

For this rapid review, we followed the Cochrane methods [10,11] and the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [12] for reporting results. This review was registered in PROSPERO (CRD42021234185).

3.1. Inclusion criteria

We included studies that used comparative or non-comparative study designs. Case series were only included if they reported more than 50 exposed pregnant persons. We also included experimental studies of any sample size with exposed pregnant animals. We excluded systematic reviews (SRs) but explored their reference lists as an additional primary study source.

The exposures or interventions of interest are the COVID-19 candidate vaccines that the COVAX-MIWG selected for review in August 2020; or the vaccine platforms (protein/subunit, vectored, nucleic acid/mRNA-LNP); or the components (antigen, vehicle, construct, adjuvants, lipid nanoparticles or other components) used by the selected COVID-19 vaccines (Table 1). At least one of these exposures was explicitly described in the report.

We considered outcomes concerning exposure to the vaccines based on the reported gestational age at vaccination (based on validated methods including ultrasound or last menstrual period [LMP] for human studies). We used the 21 standardized case definitions developed by the Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) of prioritized obstetric and neonatal outcomes based on the Brighton Collaboration process [13]. The ten GAIA obstetric outcomes include hypertensive disorders of pregnancy, maternal death, non-reassuring fetal status, pathways to preterm birth, postpartum hemorrhage, abortion/miscarriage, antenatal bleeding, gestational diabetes, dysfunctional labor, and fetal growth retardation. The 11 neonatal outcomes include congenital anomalies, neonatal death, neonatal infections, preterm birth, stillbirth, low birth weight, small for gestational age, neonatal encephalopathy, respiratory distress, failure to thrive, and microcephaly.

For this rapid review, we considered the integrative outcome “safety concerns” as any statistically significant adverse outcome reported in the comparative studies, or unexpected frequencies with respect to the published incidences in the peer-reviewed literature reported in uncontrolled studies. We described all the adverse events as they were reported by the authors of the original studies. For the full review, safety outcomes will be analyzed according to the US Food and Drug Administration (FDA) Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials [14]. An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study treatment [15]. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. These include local reactions at the injection site (pain, tenderness, erythema, edema, pruritus, other) and systemic reactions (fever ≥ 38 °C or 100.4°F, headache, malaise, myalgia, fatigue, etc.). We will also consider other post-vaccination medical events (unsolicited in the studies, reported by organ system as per Medical Dictionary for Regulatory Activities - MedDRA) [16].

We will use the classification in a four grade for the severity of AEs. We also will consider other classifications of AEs commonly reported in safety studies, including:

– Medically attended adverse events (MAEs): AEs leading to an otherwise unscheduled visit to or from medical personnel for any reason, including visits to an accident and emergency department.
Table 1
Main characteristics of the vaccines that were selected for review by the COVAX-MIWG# in August 2020.

| Platform       | Developer/manufacturer | Vaccine candidates | Construct                                                                 | Adjuvant          | Dose/Schedule                  |
|----------------|------------------------|--------------------|---------------------------------------------------------------------------|-------------------|--------------------------------|
| Protein/subunit| Novavax                | SARS-CoV-2 sF      | Recombinant Spike Protein Nanoparticle vaccine Baculovirus Expressed trimeric Spike; \( \Delta F \) Baculovirus Expressed trimeric Stabilized Spike | Matrix-M\*        | Two doses at 5 \( \mu \) g with/wo Matrix M (0.21 days) |
|                | Sanofi/GSK             | Recombinant protein vaccine | Protein antigen                                                          | AS03             | 5 \( \mu \) g + AS03 (0, 21 days) |
|                | Biological E (Bio E)   | Recombinant protein vaccine | Protein antigen                                                          | Alhydrogel (Alum)/CpG 1018 | Two doses (0.28 days) |
|                | Coalition for Epidemic Preparedness Innovations (CEPI) ||                                                                           |                   |                                |
|                | Clover                 | Recombinant protein vaccine | S-protein trimer                                                          | AS03/CpG1018 (in CHO cells) | Two doses (0.21 days) |
|                | Xiamen Innovax Biotech & GSK |                       |                                                                           |                   |                                |
| Vected         | Merck Sharp & Dohme Corp.* | Recombinant replicating virus | Recombinant Vesicular stomatitis virus (VSV)-\( \Delta G \)-spike, (in MRC or Vero cells) Replication Incompetent Ad26; Stab. Spike; \( \Delta F \); TM | No                | One dose (TBD) |
|                | Johnson & Johnson/ Jansen | Non-replicating viral vector |                                                                           | No                |                                |
|                | U Oxford/AstraZeneca   | Non-replicating viral vector | ChAdOx1 wild type Spike; TM                                               | No                |                                |
| Nucleic acid/mRNA-LNP | Moderna                | Encapsulated mRNA-1273 | mRNA: encodes 2P-stabilized Spike, TM, FI                               | No                | Two doses at 5 \( \times 10^{10} \) vp; 2 doses at 5 \( \times 10^{10} \) vp; 2 doses at 100 \( \mu \) g (0.28 days) |
|                | BioNTech/Pfizer        | BNT162a b2          | mRNA: encodes stabilized SARS-CoV-2 Spike                                | No                | Two doses at 100 \( \mu \) g (0.28 days) |
|                | CureVac                | mRNA nCoV-19        | mRNA/LNP full-length S-protein stabilized                                | No                | Two doses at 30 \( \mu \) g (0, 21 days) |

# COVAX-MIWG: COVID-19 Vaccines Global Access - Maternal Immunization Working Group.
* Merck discontinued the development of this vaccine on January 25, 2021.
LNP: lipid nanoparticle; AS: Adjuvant System; CpG: Cytosine phosphoGuanosine; MRC: Human Fetal Lung Fibroblast Cells; CHO: Chinese hamster ovary; TM: transmembrane domain; S: Spike; FI: formalin-inactivated; sF: recombinant Spike.

- Serious adverse events (SAEs): AEs that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or resulted in a congenital anomaly/birth defect in the child of a study participant.
- Adverse events of special interest (AESIs): AEs worthy of closer follow-up over six months post-vaccination. These include vaccine-associated enhanced diseases such as multisystem inflammatory syndrome in children or adults (MIS-C/A).

The operative definition of each specific AE was reported elsewhere (PROSPERO- CRD42021234185).

3.2. Search strategy

We searched published and unpublished studies, without restrictions on language or publication status, from inception date to February 2021 (See the full search strategies and search terms in Appendix 1) in the Cochrane Library databases, MEDLINE, EMBASE, Latin American and Caribbean Health Sciences Literature (LILACS), Science Citation Index Expanded (SCI-EXPANDED), China Network Knowledge Information (CNKI), WHO Database of publications on nCoV-2019LSR, Maternal and Child Health, Nutrition: John Hopkins Centre for Humanitarian health, the LOVE database.

We also searched reference lists of relevant primary studies and systematic reviews retrieved by the search strategy and the adverse events/safety reported in active COVID-19 pregnancy registries. The Food and Drug Administration (FDA), the European Medicines Agency (EMA), and clinical trials websites will be searched for the full review. We will then contact original authors and experts in the field for clarification or to obtain extra information. For the full review, we will re-run the search strategy, between March 2021 and the current date and time, to capture any new evidence in databases.

3.3. Selection of studies, data extraction, and assessment of the risk of bias in included studies

Pairs of authors independently screened each identified record by title and abstract and retrieved all the full texts of the potentially eligible studies. Pairs of review authors independently examined the full-text articles for compliance with the inclusion criteria and selected the eligible studies. We resolved any disagreements by discussion. We documented the selection process with a PRISMA flow chart [12], conducted through COVIDENCE [17], a software for systematic reviews.

Pairs of review authors independently extracted data from eligible studies using a data extraction form designed and pilot-tested by the authors. Any disagreements were resolved by discussion. Extracted data included study characteristics and outcome data. Where studies have multiple publications, we collated multiple reports of the same study under a single study ID with multiple references.

In Appendix 2, we describe the risk of bias assessment tools used for each study design. Briefly, we independently assessed the risk of bias of the included clinical trials using the Cochrane risk of bias assessment tool [18]. We used the Cochrane EPOC group tools [19] to assess controlled before-after studies (CBAs), nationwide uncontrolled before-after studies (UBAs), interrupted time series (ITSs), and controlled-ITSs (CITSs). We rated the risk of bias in each domain as “low”, “high”, or “unclear”. For observational cohort, case-control, cross-sectional, and case-series studies we used the NHI Quality Assessment Tool [20]. After answering the different signaling questions “Yes”, “No”, “Cannot determine”, “Not applicable”, or “Not reported”, the raters classified the study quality as “good”, “fair”, or “poor”. For consistency with the other
designs, we use the classifications low, high, or unclear risk of bias, respectively.

3.4. Data synthesis

The primary analysis was the comparison of participants exposed and unexposed to the vaccines or their components. For this rapid review, we tabulated the study exposure characteristics and compared them against the unexposed. We analyzed the results of each study to determine any safety concerns as “Yes”, “No”, or “Unclear”.

Data from non-comparative studies, including registries, were collected and analyzed in the context of background rates of neonatal and obstetric outcomes. For specific indicators, we take into consideration group-specific definitions such as low-to-middle-income countries (LMICs).

We described the effect estimates as reported by the authors of the included studies. For dichotomous data, we used the numbers of events in the control and intervention groups of each study to calculate Risk Ratios (RRs), Hazard Ratios (HRs), or Mantel-Haenszel Odds Ratios (ORs).

We planned to conduct meta-analysis and subgroup analyses by the trimester of exposure and sensitivity analysis restricted to studies with a low risk of bias. However, these were not pursued for this rapid review, given the lack of safety concerns identified. We plan to perform a meta-analysis and present GRADE 'Summary of findings' tables [10,21] for the full review as was previously stated (PROSPERO- CRD42021234185).

4. Results

We retrieved 6756 records and 12 COVID-19 pregnancy registries from the search strategy. 266 potentially eligible studies were assessed by full-text, and 227 were excluded, mainly because of wrong exposure or intervention (114) or insufficient information (67). We included 38 clinical and non-clinical studies, involving 2,398,855 pregnant persons and 56 pregnant animals from 39 reports.[4,22–59] (Fig. 1). The list of excluded studies and the reasons for exclusion is presented in Appendix 3.

4.1. Description of studies

The characteristics of included studies are described in Table 2. The most frequent study design was cohort studies (n = 22) followed by surveillance studies (n = 8), controlled trials (n = 5), and registry analyses (n = 3). Twenty-nine of the included studies (76%) allowed comparisons between vaccinated and unvaccinated pregnant persons (n = 26) or were conducted in animals (n = 3). Nine out of the 38 studies (24%) were abstracts.

The most frequent study location was the USA (n = 7), followed by Sweden and the United Kingdom (n = 5 each), Australia, Canada, and Denmark (n = 3 each), Cuba, France, and Netherlands (n = 2 each), and Argentina, Belgium, Finland, Germany, Norway, and multi-country (n = 1 each). Only 4 out of 37 studies (11%) involved LMICs [27,36,45,50].

Only 3 out of 37 studies were conducted on animals (8%) [28,33,58]. Most of the studies reported exposures during the three trimesters (n = 17), only the first trimester (n = 5), and the second and third trimester (n = 4). The time of exposure was not reported in six studies.

We only identified one COVID-19 vaccine study reporting exposure to mRNA-LNP from Pfizer & Moderna COVID-19 vaccines [4]. The most frequent exposures were to the AS03 adjuvant (536,240 pregnant participants from 23 studies) and aluminum-based adjuvants (1,861,462 pregnant participants from 11 studies) (Table 3). AS03 was the adjuvant of several A/H1N1 pandemic influenza vaccines (Pandemrix® and Arepanrix), while the influenza vaccine Equilis® used ISCOM-Matrix [32]. Aluminum phosphate was used in the testing of candidate Respiratory Syncytial Virus Fusion (RSV F) vaccines in pregnant persons [28,44,48] (n = 3). Aluminum phosphate was also used in Tdap vaccines [36,46,55] (n = 3). Different aluminum salts were used in Hepatitis vaccines [23,29,30,37,47,48]. One study reported the use of the ChAdOx1 vector for a Rift Valley fever vaccine [58].

The 12 COVID-19 and pregnancy registries identified (UKOS, PAN-COVID, BPSU, NPC-19, EPICENTRE, perICOVID, INTERCOVID, PregCOV-19LSR, PRIORITY, COVI-PREG), OTIS/MotherToBaby, CHOPAN, and V-safe registries) are presented in Appendix 4.

4.2. Risk of bias in included studies

The risk of bias for the included controlled trials is presented in Table 4 and for the included observational studies in Table 5. We assessed the 38 included reports. Among the five RCTs, two (40%) presented a high risk of bias in the randomization process, and one (20%) in the blinding of participants and personnel. Among the 33 observational study reports, 14 were classified as “good” (43%), 12 as “fair” (36%), and seven as “poor” (21%).

4.3. Outcomes of exposures

The results of included studies are described in Table 2. There were 13 pregnancy-related outcomes (26 reports), eight neonatal outcomes (19 reports), and nine maternal outcomes (13 reports). The most-reported pregnancy outcomes were preterm delivery (n = 12), stillbirth (n = 9), spontaneous abortion (n = 9), fetal growth restriction/small gestational age (n = 8), and fetal death (n = 6). The most reported neonatal outcomes were congenital anomalies (n = 9) and low birth weight (n = 8), and the most reported maternal outcomes were local reactions (n = 7), systemic reactions (n = 5), and serious adverse events (n = 6).

The adjusted relative effects comparing exposed vs. not exposed pregnant participants by vaccine components/platforms were summarized in Table 3. None of the available exposures, including AS03, aluminum phosphate, or aluminum salts only, was statistically associated with adverse outcomes. AS03 showed a statistically lower frequency of very preterm aRR 0.73 (95%CI 0.58–0.91) [25] and peripartum complications aOR 0.65 (95%CI 0.42–0.99) [54], and aluminum salts showed lower stillbirth aHR 0.49 (95% CI 0.29–0.84) [55]. The lack of more comparative information regarding “safety concerns” precludes further subgroup analysis by exposure.

Of the 37 included studies, 36 (97%) concluded that there was no evidence of safety concerns. Only one study [56], reported as abstract, mentioned unclear safety concerns regarding the 9,026 pregnancies ending in a delivery that had a record of the swine flu vaccine during or just before their pregnancy. The authors reported that they may not have captured early pregnancy losses, that some misclassification of outcome may have occurred, or residual confounding may have been present after adjusting for age and chronic comorbidity. However, the full-text manuscript reported one year later by these authors [57], including 9,445 persons vaccinated with the swine flu vaccine before or during pregnancy, found no difference in the hazard of fetal loss during weeks 25–43 and a lower hazard of fetal loss than unvaccinated pregnancies in gestational weeks 9–12 and 13–24.

The planned subgroup analyses by the trimester of exposure and sensitivity analysis, restricted to studies with low risk of bias, were not conducted, given the lack of reported safety concerns in every study.
Table 4 shows the characteristics of the 12 identified COVID-19 and pregnancy registries, with potential data on safety/adverse events. The USA and the UK were the most represented countries. Some large registries are multinational, such as EPICENTRE, COVIPREG, or PAN-COVID, which gathers data from 42 countries. Most registries include information on obstetric/pregnancy outcomes like early pregnancy loss, fetal growth, stillbirths, and delivery outcomes. All of them include neonatal and infant outcomes. Additionally, UKOSS and V-safe include specific vaccination information on the pregnant population. PeriCOVID was the only registry that collected blood samples. More detailed information on the relevant information from these registries will be described in the full systematic review, which is currently ongoing.

We also identified three ongoing studies in the COVID-19 vaccine tracker, developed by the Vaccine Centre at the London School of Hygiene and Tropical Medicine, which contains information from the WHO, the Milken Institute, and clinicaltrials.gov databases [60]. A phase-2 trial, assessing the Ad26.COV2.S vaccine (a monovalent vaccine composed of a recombinant, replication-incompetent adenovirus type 26 vector) [61], and a phase-2/3 trial, assessing the BNT162B2 vaccine (an RNA vaccine) [62], are being conducted in the United States, Australia, Brazil, Canada, Finland, South Africa, Spain, and in the United Kingdom. In addition, a phase-4 nonrandomized controlled study is being conducted in Belgium to verify if SARS-CoV-2 specific antibodies can be found in blood serum and milk of lactating mothers vaccinated with the CX-024414 vaccine (mRNA vaccine) [63].

5. Discussion

Through this rapid review of studies of vaccine components and platforms also used by COVID-19 vaccines, we found no evidence of safety concerns regarding the COVID-19 vaccines that the COVAX MIWG selected for review in August 2020, their components, or platforms used in other vaccines during pregnancy.

None of the adjusted relative effects comparing exposed vs. not exposed pregnant participants of the available exposure results were statistically associated with adverse outcomes. Only AS03 showed a statistically lower frequency of very preterm [25] and peripartum complications [54], and aluminum salts showed lower stillbirth aHR 0.49 (95%CI 0.29–0.84) [55]. Uncontrolled studies, in
| Study ID | Study design | Country | Population | Trimester exposure | Vaccine names | Exposure/ intervention* | Control | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies) | Original study authors s’ conclusion | Safety concerns |
|----------|--------------|---------|------------|---------------------|--------------|------------------------|---------|------------------------------------------------------------------------|-------------------------------|----------------|
| Baum 2015 [22] | Cohort studies | Finland | Pregnant women | 2 + 3 | Pandemrix | AS03 | No exposure | Stillbirth: aHR 1.05 (95% Confidence Interval [CI] 0.66–1.65) Early neonatal death: aHR 1.02 (0.43–2.40) Moderately preterm (28–36 weeks): aHR 1.00 (0.89–1.12) Very preterm (<28 weeks): aHR 0.90 (0.55–1.45) Moderately low birth weight (1500 g–2499 g): aHR 1.05 (0.90–1.21) Very low birth weight (<1500 g): aHR 0.84 (0.61–1.16) Fetal growth restriction: aHR 1.17 (0.98–1.40) | The risk of adverse pregnancy outcomes was not associated with the exposure to the AS03 adjuvanted pandemic influenza vaccine. | No |
| Celzo 2020[23] | Surveillance | Belgium | Pregnant women | 1 + 2 + 3 | Havrix, Engerix-B or Twinrix | Alhydrogel (Alum)/CpG 1018 | No control | Pregnancy-related adverse event (Havrix 64/378; Engerix-B 23/339; Twinrix 103/199) Congenital anomalies/birth defects (Havrix 19/378; Engerix-B 29/339; Twinrix 10/199) Major birth defects (Havrix 17/19; Engerix-B 20/29; Twinrix 7/10) Spontaneous abortions (Havrix 43; Engerix-B 57; Twinrix 26) | No indication of any concerning pattern of adverse pregnancy outcomes following exposure to any of the 3 vaccines during pregnancy | No |
| Chavant 2013 [24] | Surveillance | France | Pregnant women | NR | Pandemrix | AS03 | No control | Fever and Flu-like symptoms: 37/56 (65.9%) Headaches: 9/56 (17.6%) Local reactions: 37/56 (65.9%) Congenital anomalies: 1/56 (1.4%) Preterm birth (<37 weeks): aRR (95% CI) 0.95 (0.88, 1.02) Very preterm birth (<32 weeks): aRR 0.73 (0.58, 0.91) Small for gestational age: below 10th percentile: aRR 0.90 (0.85, 0.96) Small for gestational age: below 3rd percentile: aRR | Exposure to the A(H1N1) 2009 pandemic influenza vaccine during pregnancy does not increase the risk of adverse pregnancy outcomes. | No |
| Fell 2012 [25] | Safety registry | Canada | Pregnant women | 2 + 3 | Pandemrix | AS03 | No exposure | Second- or third-trimester H1N1 vaccination was associated with improved fetal and neonatal outcomes during the recent pandemic. | No |
| Study ID | Study ID | N   | Study design | Country       | Population          | Trimester exposure | Vaccine names | Exposure/ intervention* | Control | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies) | Original study authors s’ conclusion | Safety concerns |
|----------|----------|-----|--------------|---------------|---------------------|--------------------|---------------|----------------------------|---------|-----------------------------------------------------------------|--------------------------------------|-----------------|
| Folkenberg 2011 [26] | Folkenberg 2011 [26] | 5,772 | Surveillance | Denmark       | Pregnant women      | NR                 | Pandemrix | AS03 | No control | 0.81 (0.72, 0.92) 5-minute Apgar score below 7: aRR 0.97 (0.82, 1.14) Fetal death: aRR 0.66 (0.47, 0.91) Uterine contractions: 2/12 Spontaneous abortions: 4/12 Stillbirth: 1/12 | No strong signals of any unknown or serious adverse events associated with influenza A/H1N1v vaccination in Denmark. | No |
| Galindo Santana 2011 [27] | Galindo Santana 2011 [27] | 80,317 | Cohort studies | Cuba         | Pregnant women      | 1 + 2 + 3          | Pandemrix | AS03 | No control | Adverse effects 615/80,317 (0.8%) of the vaccinated pregnant women (fever 32.4%; headache 30.3%; vomiting 12%; local reactions 9%; arthralgia 6.9%; dizziness 5%; allergic manifestations 3%; spontaneous abortions 0.3%; increase in uterine contractions 0.3%) | No safety problem is associated to the Pandemrix vaccine. | No |
| Glenn 2015 [28] | Glenn 2015 [28] | 71 | RCT            | USA         | Animals            | 3                  | RSV F vaccine | Protein/subunit; Nanoparticles; aluminum phosphate | Another intervention & placebo | Delivery rate Placebo: 80%; RSV F: 80% and RSV F + AlP04: 90% 3 stillbirths placebo vs 3 stillbirths in the adjuvanted RSV F group Vaccine-related fevers/chills: 25/77 (32%) /8/16 [50%] in non-pregnant women; p = 0.25). Fetal growth restriction: 0/13; Preecclampsia/gestational hypertension: 0/13 Preterm delivery: 1/13; Death: 0/13 The cumulative symptom score after the 1st dose in all groups was low and after the 2nd dose, the cumulative symptom score (median (IQR) 2 (1–3), 3 (2–4), and 2.5 (1–4.5) in pregnant, lactating, and non–pregnant groups respectively with respect to cumulative symptom score. | The RSV F vaccine was safe. The rates of pregnancy and stillbirth were similar between controls and vaccinees. | No |
| Gray 2021 [4] | Gray 2021 [4] | 84 | Cohort studies | USA         | Pregnant women      | 1 + 2 + 3          | COVID-19 (Pfizer & Moderna) | Nucleic acid/ mRNA | Not pregnant | There was no significant difference between pregnant, lactating, and non–pregnant groups respectively with respect to cumulative symptom score. | No |

(continued on next page)
| Study ID | Study ID | N    | Study design | Country      | Population          | Trimester exposure | Vaccine names                                                                 | Exposure/ intervention* | Control                                                                 | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies) | Original study authors s’ conclusion | Safety concerns |
|----------|----------|------|--------------|--------------|---------------------|--------------------|-------------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------|----------------|
| Groom 2018 [29] | Groom 2018 [29] | 1,399 | Cohort studies | USA          | Pregnant women      | 1 + 2 + 3           | Recombivax, Engerix or Twinrix, Aluminum hydrophosphate sulphate, Alhydrogel (Alum) Aluminum phosphate | Not Hep B vaccinated (other vaccines or unvaccinated) | Gestational hypertension: aOR (95%CI) 1.02 (0.80–1.30), Gestational diabetes: aOR 1.06 (0.91–1.23), Pre-eclampsia/eclampsia: aOR 1.07 (0.84–1.36), Cesarean delivery: aOR 1.01 (0.91–1.13), Pre-term birth (<37 weeks): aOR 1.14 (0.94–1.39), Low birth weight (<2500 g): aOR 1.21 (0.96–1.52), Small for gestational age at birth: aOR 1.13 (0.94–1.37) | There were no significant associations between Hep B exposure during pregnancy and maternal and neonatal outcomes. No increased risk for the adverse events that were observed among women or their offspring. | No | 
| Groom 2019 [30] | Groom 2019 | 1140 | Cohort studies | USA          | Pregnant women      | 1 + 2 + 3           | Hepatitis A, Aluminium hydroxide                                                | Not Hep A vaccinated (other vaccines or unvaccinated) | Gestational hypertension: aOR 0.85 (0.64–1.15), Gestational diabetes: aOR 0.93 (0.78–1.11), Pre-eclampsia/eclampsia: aOR 0.92 (0.69–1.24), Cesarean delivery: aOR 1.01 (0.91–1.13), Pre-term birth (<37 wks): aOR 0.83 (0.65–1.07), Low birth weight (<2500 g): aOR 1.05 (0.81–1.37), Small for gestational: aOR 1.32 (1.09–1.60, likely due to unmeasured confounding) | HepA vaccination during pregnancy was not associated with an increased risk for a range of adverse events examined among pregnancies resulting in live births, but an identified association between maternal HepA and SGA infant outcomes, while likely due to unmeasured confounding, warrants further exploration. | No | 
| Guo 2010 [31] | Guo 2010 [30] | 875  | Cohort studies | Canada       | Pregnant women      | NR                 | Arepanrix AS03                                                                | No exposure              | Fetal loss: 7/550 (1.3%) vaccinees vs 11/325 (3.3%) unvaccinated, P = 0.06, Premature birth: 31/359 (8.6%) vaccinated vs 23/185 (12%) unvaccinated P = .21 Of 261 vaccinees reporting weekly data, 11 (4.2%) reported an adverse event requiring missed work or an MD visit within 7 days of vaccination, most commonly acute respiratory illness (N = 7). Only one event (arm numbness) was thought to be vaccine related. No serious adverse events were reported. | Results to date suggest that pandemic vaccines were safe. | No |
| Study ID          | Study design | N     | Country    | Population      | Trimester exposure | Vaccine names | Exposure/ intervention* | Control                                                                                                                                  | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies)                                                                 | Original study authors s’ conclusion                                                                 | Safety concerns |
|-------------------|--------------|-------|------------|-----------------|-------------------|---------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|-----------------|
| Haberg 2013 [32]  | Safety registry | 63,367 | Norway     | Pregnant women  | 2 + 3             | Pandemrix      | AS03                   | No exposure                                                                                                                              | Fetal death HR IC95%: 0.88 (0.66–1.17) Preterm delivery HR 1.00 (0.93–1.09) Low birth weight at term HR 0.90 (0.76–1.08) Low Apgar score at term HR 1.08 (0.91–1.28) | There is no evidence of association between vaccination and fetal death, preterm delivery, low birth weight at term, and low Apgar score at term | No              |
| Heldens 2009 [33] | CT           | 10    | Netherlands | Animals        | 3                 | Equilis Prequenza T | ISCOM-Matrix | No exposure                                                                                                                              | Local reaction (swelling): 3/10 (in each dose) Pyrexia: 0/10 Systemic reactions: 0/10 The effects in the non-intervention was not reported | The vaccine was shown to be safe in pregnant mares, foals and is used safely since 2 years as a commercial vaccine in Europe. | No              |
| Jonas 2015 [34]   | Cohort studies | 41,183 | Sweden     | Pregnant women  | 1 + 2 + 3         | Pandemrix      | AS03                   | No exposure & pre-vaccination group                                                                                                     | Stillbirth: aHR IC95%: 0.88 (0.59–1.30) Early neonatal death: aHR 0.82 (0.46–1.49) Later death: aHR 0.78 (0.52–1.19) Gestational diabetes aOR (IC95%): 0.94 (0.81–1.09) Pre-eclampsia: aOR 0.99 (0.92–1.07) | AS03 adjuvanted H1N1 vaccination during pregnancy does not affect the risk of stillbirth, early neonatal death, or later mortality in the offspring. | No              |
| Källén 2012 [35]  | Cohort studies | 18,612 | Sweden     | Pregnant women  | 1 + 2 + 3         | Pandemrix      | AS03                   | No control                                                                                                                                | Adverse events following immunization (pregnant women): 1.46/100,000 Adverse events following immunization vaccine 0.43/100,000 | Both vaccines presented a suitable safety profile. Since 2012 a downward trend in pertussis mortality was evident and no deaths from influenza in vaccinated were notified in pregnant women | No              |
| Katz 2016 [36]    | Safety registry^a | 1,845,379 | Argentina  | Pregnant women  | 1 + 2 + 3         | Tdap          | Protein/subunit & aluminum phosphate | No control                                                                                                                                | Healthy term deliveries: 24 (60%) Heplisav-B vs 11 (55%) Engerix-B Spontaneous abortions: 3 (7.5%) Heplisav-B vs 2 (10%) Engerix-B Congenital anomaly: 1 (2.5%) Heplisav-B vs 1 (5%) Engerix-B | Heplisav-B shows similar fetal outcomes compared with Engerix-B. | No              |
| Kushner 2020 [37] | Cohort studies^a | 59    | Australia  | Pregnant women  | 1                 | Heplisav B     | Aluminum phosphate/ CpG1018 | No control                                                                                                                                | Healthy term deliveries: 24 (60%) Heplisav-B vs 11 (55%) Engerix-B Spontaneous abortions: 3 (7.5%) Heplisav-B vs 2 (10%) Engerix-B Congenital anomaly: 1 (2.5%) Heplisav-B vs 1 (5%) Engerix-B | Heplisav-B shows similar fetal outcomes compared with Engerix-B. | No              |
| Study ID | Study ID | N   | Study design | Country          | Population  | Trimester exposure | Vaccine names | Exposure/ intervention* | Control                                                                 | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies)                                                                 | Original study authors s’ conclusion | Safety concerns |
|----------|----------|-----|--------------|------------------|--------------|--------------------|---------------|--------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-----------------|
| Lacroix 2010 [38] | Lacroix 2010 [37] | 100,000 | Surveil-lance\(^A\) | France | Pregnant women | NR | Pandemrix | AS03 | No control | Stillbirths: 1 (2.5%) Heplisav-B vs 0 (0%) Engerix-B | The French National Pharmacovigilance of A (H1N1) vaccination in pregnant women between October 2009 and March 2010, reported 13 intra-uterine deaths and 12 spontaneous abortions. | No causal relationship between immunization and in utero fetal death or spontaneous abortion was established. | No |
| Läkemedelsverket 2010 [39] | Läkemedelsverket 2010 [38] | 30,000 | Report | Sweden | Pregnant women | 1 + 2 | Pandemrix | AS03 | No control | Suspected adverse events: 50/30,000 (0.17%) Miscarriages: 31/30,000 (0.10%) Intrauterine fetal deaths: 7/30,000 (0.02%) | The low number of reports with no defined risk profile would indicate that the vaccination with Pandemrix does not increase the risk for miscarriage or intrauterine fetal death. | No |
| Layton 2011 [40] | Layton 2011 [39] | 92 | Cohort studies\(^A\) | United Kingdom | Pregnant women | 1 + 2 + 3 | Pandemrix | AS03 | No control | Miscarriages: 4/92 (4.3%) Congenital problems: 6/92 (6.5%) | No safety conclusion | No |
| Levi 2012 [41] | Levi 2012 [40] | 6,989 | Cohort studies | Denmark | Pregnant women | 1 + 2 + 3 | Pandemrix | AS03 | No exposure | Serious congenital malformation (1st trimester): 5.5% vs 4.5% unvaccinated Premature birth or low birth weight was also equally common in both groups, regardless of it time of vaccination. | It appears to be safe even during the pregnancy to be vaccinated against the H1N1 virus. | No |
| Ludvigsson 2013 [43] | Ludvigsson 2013 [42] | 13,297 | Cohort studies | Sweden | Pregnant women | 1 + 2 + 3 | Pandemrix | AS03 | No exposure | Low birth weight < 2,500 g: aOR (IC95%) 0.91 (0.79–1.04) Preterm birth < 37 weeks: aOR 0.99 (0.89–1.10) Small for gestational age: aOR 0.97 (0.90–1.05) Low Apgar score at 5 min < 7: aOR 1.05 (0.84–1.31) Cesarean section: aOR 0.94 (0.89–0.99) | H1N1 AS03-adjuvanted vaccine during pregnancy, does not appear to adversely influence maternal or neonatal outcomes when used in different stages of pregnancy. | No |
| Ludvigsson 2016 [42] | Ludvigsson 2016 [41] | 40,983 | Cohort studies | Sweden | Pregnant women | 1 | Pandemrix | AS03 | Siblings | Congenital malformation: aOR (IC95%) 0.98 (0.89–1.07) Congenital heart disease: aOR 0.98 (0.84–1.15) Oral cleft: aOR 1.14 (0.67–1.94) Limb deficiency: aOR 0.90 (0.36–2.28) | When intrafamilial factors were taken into consideration, H1N1 vaccination during pregnancy did not seem to be linked to overall congenital malformation in offspring. | No |
| Study ID          | Study design | N   | Country   | Population | Trimester exposure | Vaccine names                                                                 | Exposure/intervention* | Control                                                                 | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies) | Original study authors s’ conclusion | Safety concerns |
|-------------------|--------------|-----|-----------|------------|--------------------|-------------------------------------------------------------------------------|------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------|-----------------|
| Mackenzie 2012   | Cohort studies | 128 | United Kingdom | Pregnant women | 1 + 2 + 3 | Pandemrix A503 | No exposure | Miscarriages: 4/97 (4.1%) Potentially congenital abnormalities: 6/97 (6.2%) Stillbirths: 0/97 (0%) Local injection-site reactions: 40.7% vs. 9.9% placebo; P < 0.001 | Fever within 7 days: 1.2% vs 1.6% Systemic reaction: 41.2% vs 38.6% Serious adverse event: 29.8% vs 28.8% Any infant adverse event 82.3% vs 83% Serious adverse event: 44.3% vs 46.4% Serious adverse event with outcome of death: 0.6% vs 0.8% Preterm birth (<37 weeks): aRR (95% CI) 0.99 (0.75–1.32) Low birth weight at term (<2500 g): aRR 1.19 (0.61–1.11) Small for gestational age (<10th percentile): aRR 1.09 (0.86–1.37) | Overall, no significant safety issues were identified. | RSV F protein nanoparticle vaccination in pregnant women was safe | No |
| Madhi 2020       | RCT | 4,636 | Multi-country | Pregnant women | 2 + 3 | RSV F vaccine, Baculovirus/Aluminum phosphate | Placebo | Solicited AEs: 15/22 (68.2%) vs 10/28 (35.7%) Severe solicited AEs 0/22 vs 0/28 Local solicited AEs 13/22 (59.1%) vs 1/28 (3.6%) Systemic solicited AEs 6/22 (27.3%) vs 10/28 (35.7%) | The vaccine was well tolerated; no meaningful differences in pregnancy or infant outcomes were observed between study groups. Suggesting good tolerability of the RSV F vaccine among pregnant women | This review of VAERS reports did not identify any concerning pattern of AEs in pregnant women or their infants following maternal Hep A or Hep B immunizations during pregnancy. Our analysis of VAERS reports involving hepatitis B vaccination during pregnancy did not identify any new or unexpected safety concerns. | No |
| McHugh 2019      | Cohort studies | 2,706 | Australia | Pregnant women | 1 + 2 + 3 | Tdap | No exposure | Pregnancy AEs: 41/139 (29.4%) Non-pregnancy specific outcomes: 21/139 (15.1%) Infant/neonatal outcomes: 12/139 (8.6%) No AE reported: 65/139 (46.8%) Pregnancy-specific AEs: 61 (45.4%) Non-pregnancy specific AEs: 35 (31.8%) Infant outcomes: 22 (20.0%) | No significant associations were found between pertussis vaccination in pregnancy and adverse birth outcomes, regardless of the trimester of pregnancy. | No |
| Moro 2014        | Surveillance | 139 | USA | Pregnant women | 1 | Havrix, Vaqta, Twinrix | Aluminum hydrophosphate sulphate, Alhydrogel (Alum) | No control | Pregnancy AEs: 119/139 (87.4%) | This review of VAERS reports did not identify any concerning pattern of AEs in pregnant women or their infants following maternal Hep A or Hep B immunizations during pregnancy. Our analysis of VAERS reports involving hepatitis B vaccination during pregnancy did not identify any new or unexpected safety concerns. | No |
| Moro 2018        | Surveillance | 192 | USA | Pregnant women | 1 + 2 + 3 | Recombivax Engerix-b, Twinrix, Comvax, Pediarix | Aluminum hydrophosphate sulphate, Alhydrogel (Alum) | No control | Pregnancy-specific AEs: 61 (55.4%) Non-pregnancy specific AEs: 35 (31.8%) Infant outcomes: 22 (20.0%) | No significant associations were found between pertussis vaccination in pregnancy and adverse birth outcomes, regardless of the trimester of pregnancy. | No |
| Muñoz 2019       | RCT | 50 | USA | Pregnant women | 3 | RSV F vaccine, Baculovirus/Aluminum phosphate | Placebo | Solicited AEs: 15/22 (68.2%) vs 10/28 (35.7%) Severe solicited AEs 0/22 vs 0/28 Local solicited AEs 13/22 (59.1%) vs 1/28 (3.6%) Systemic solicited AEs 6/22 (27.3%) vs 10/28 (35.7%) | The vaccine was well tolerated; no meaningful differences in pregnancy or infant outcomes were observed between study groups. Suggesting good tolerability of the RSV F vaccine among pregnant women | No |

(continued on next page)
| Study ID          | Study ID          | N     | Study design | Country       | Population | Trimester exposure | Vaccine names | Exposure/ intervention* | Control | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies)                                                                 | Original study authors s’ conclusion | Safety concerns |
|------------------|------------------|-------|--------------|---------------|-------------|-------------------|---------------|--------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|----------------|
| Núñez Rojas 2010 | Núñez Rojas 2010 | 451   | Cohort studies | Cuba          | Pregnant women | 1               | Pandemrix      | AS03                     | No exposure | Any unsolicited AE 22/22 (100.0%) vs 28/28 (100.0%) Severe unsolicited AE 3/22 (13.6%) vs 4/28 (14.3%) Severe & related unsolicited AE 0/22 vs 0/28 Any medically attended AE 18/22 (81.8%) vs 25/28 (89.3%) Any serious AE (SAE) 3/22 (13.6%) vs 1/28 (3.6%) 34/451 Vs control group 21/205 (OR:0.71) for some condition, minor or major. 64.7% of findings in the vaccinated group were located in the kidneys (62.2% were renal ectasy, either unilateral or bilateral) Vaccination against influenza virus A H1N1 did not increase the risk of birth defects when applied during the first trimester of gestation in the sample studied | Núñez Rojas 2010 [49] | No |
| Oppermann 2012   | Oppermann 2012   | 90    | Cohort studies | Germany        | Pregnant women | 1               | Pandemrix      | AS03                     | No exposure | Systemic adverse reactions: 23/90 (25.6%) Local reactions: 64/90 (71.1%) Spontaneous abortions: 3/90 (3.3%) Major birth defects in gestational weeks 4–10: prevalence OR (POR) 1.24 (0.57–2.71) Preterm birth: POR: 0.99 (0.84–1.17) Small size for gestational age: POR: 0.97 (0.86–1.09) Fetal death: HR [95%CI] 0.79 (0.53–1.16) Spontaneous abortion HR 1.11 (0.71–1.73) Stillbirth: HR 0.44 (0.20–0.94) The results of our study do not indicate a risk for the pregnant woman and the developing embryo/fetus after H1N1 vaccination. | Oppermann 2012 [50] | No |
| Pasternak 2012   | Pasternak 2012   | 54,585| Cohort studies | Denmark        | Pregnant women | 1 + 2 + 3       | Pandemrix      | AS03 Propensity score   | Exposure to an adjuvanted influenza A(H1N1) pdm09 vaccine during pregnancy was not associated with a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction. | Pasternak 2012 [51,52] | No |
| Ray 2014         | Ray 2014         | 509   | Cohort studies | Canada         | Pregnant women | NR              | Pandemrix      | AS03 Inactivated non-adjuvanted H1N1 vaccine Peripartum complications: 83/199 (41.7%) nonadjuvanted vs 127/509 (25.1%) adjuvanted (aOR 1.55; IC95% 1.01–2.39) Local reaction. 7.1% Tdap and 3.2% TIV The composite outcome of peripartum complications was more common in women who received the nonadjuvanted vaccine Active vaccine safety monitoring has not identified clinically significant issues. Pregnant woman vaccinated against influenza are less likely to experience stillbirth. | Ray 2014 [53] | No |
| Rega 2016        | Rega 2016        | 5,155 | Unclear       | Australia      | Pregnant women | NR              | Aluminum phosphate | TIV & unvaccinated | | | Rega 2016 [54] | No |
| Study ID | Study ID | N   | Study design | Country    | Population | Trimester exposure | Vaccine names | Exposure/ intervention* | Control | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies) | Original study authors’ conclusion | Safety concerns |
|----------|----------|-----|--------------|------------|------------|--------------------|--------------|-------------------------|---------|--------------------------------------------------------------------------------|---------------------------------|----------------|
| Sammon 2011 | Sammon 2011 | 9,282 | Cohort studies | United Kingdom | Pregnant women | 1 + 2 + 3 | Influenza v. pandemic & seasonal | AS03 | No exposure | Spontaneous loss adjusted for age and chronic comorbidity: aRR 1.54; CI95% 1.36–1.74 | We identified an increased miscarriage risk associated with influenza vaccination during pregnancy possibility due to residual confounding | Unclear |
| Sammon 2012 | Sammon 2012 | 9,445 | Cohort studies | United Kingdom | Pregnant women | 1 + 2 + 3 | Pandemrix | AS03 | No exposure | Fetal death 9–12 weeks unadjusted HR 0.56; CI95% 0.43–0.73 Fetal death 13–24 weeks unadjusted HR 0.45; CI95% 0.28–0.73 Fetal loss 9–12 weeks unadjusted HR 0.74; CI95% 0.62–0.88 Fetal loss 13–24 weeks unadjusted HR 0.59; CI95% 0.45–0.77 | Fetal death 9–12 weeks unadjusted HR 0.56; CI95% 0.43–0.73 Fetal death 13–24 weeks unadjusted HR 0.45; CI95% 0.28–0.73 Fetal loss 9–12 weeks unadjusted HR 0.74; CI95% 0.62–0.88 Fetal loss 13–24 weeks unadjusted HR 0.59; CI95% 0.45–0.77 | No |
| Stedman 2019 | Stedman 2019 | 16 | RCT | Netherlands | Animals | 2 | ChAdOx1 RVF | Vectored Placebo | All ewes and does in the ChAdOx1 RVF (n = 8) and mock-vaccinated groups (n = 8) were in good health, with no clinical signs or other adverse events following vaccination | When administered to pregnant sheep and goats, ChAdOx1 RVF is safe | No |
| Tavares 2011 | Tavares 2011 | 267 | Cohort studies | United Kingdom | Pregnant women | 1 + 2 + 3 | Pandemrix | AS03 | No exposure | At least 1 MAE within the 31-daypost-vaccination: 59 (22.1 %) SAEs during the 181-day post-vaccination: 34 (12.7%) Observed/expected number of pregnancy outcomes by subgroup at vaccination: Spontaneous abortion: 4 (3.3%) (expected in the general population: 10–16%) Stillbirth: 0 (expected in the general population: 0.51%) Congenital anomaly: 5 (1.9%) (expected in the general population: 2.09%) Preterm delivery (<37 weeks’ gestation): 14 (5.4%) (expected in the general population: 5.6%) Very pre-term delivery (<32 weeks’ gestation): 3 (1.1%) (expected in the general population: 1.7%) Low birth weight (<2.5 kg): | The results of this analysis suggest that exposure to the AS03 adjuvanted H1N1 (2009) vaccine during pregnancy does not increase the risk of adverse pregnancy outcomes including spontaneous abortion, congenital anomalies, preterm delivery, low birth weight neonates, or maternal complications. | No |
| Study ID | N | Study design | Country | Population | Trimester | Vaccine names | Exposure/Control | Results (vaccinated vs. non-vaccinated pregnant women for comparative studies) | Safety concerns |
|----------|---|--------------|---------|------------|-----------|----------------|-----------------|-------------------------------------------------|----------------|
| 21       | 8.1%  | RCT          | Argentina, Australia, Chile, Bangladesh, Mexico, New Zealand, the Philippines, South Africa, Spain, the United Kingdom, and the United States. | 1 (8.1%) (expected in the general population: 7.1%) | Very low birth weight (<1.5 kg): 4 (1.5%) (expected in the general population: 1.2%) | NR | *See adjuvants, platforms and constructs in table 1; NR not reported; # Adjusted Hazard Ratio; aOR adjusted Odds Ratio; RCT Randomized Controlled Trial; AE Adverse Event; SAE Serious AE; MAE medically attended adverse event; USA United States of America; AOR Adjusted Odds Ratio; ALhydrogel is an aluminum hydroxide (referred to as alum). |

Nine systematic reviews consistently supported the safety of influenza vaccines during pregnancy [64–72]. In general, cohort studies showed the benefits of vaccination during pregnancy, such as significantly decreased risks for preterm birth, small for gestational age, and fetal death. However, after adjusting for the season at the time of vaccination and countries’ income level, only the reduction of fetal death remained significant [68]. There is no evidence of an association between influenza vaccination and serious adverse events in the comparative studies [69]. When assessing only major malformations, no increased risk was detected after immunization at any trimester. Neither adjuvanted nor unadjuvanted vaccines were associated with an increased risk for congenital anomalies [71].

Other systematic reviews also assessed the safety of different vaccines. One SR evaluated the safety of the hepatitis B vaccine, the pneumococcal polysaccharide vaccine, and the meningococcal polysaccharide vaccine during pregnancy and found no clear association with a teratogenic effect on the fetus, preterm labor, or spontaneous abortion [73]. Another SR evaluated the safety of vaccines frequently given to travelers on pregnant persons, such as yellow fever, MMR (mumps, measles, and rubella), influenza, Tdap (tetanus, diphtheria, and pertussis), meningococcus, or hepatitis A and B [74]. The authors concluded the safety of the influenza vaccine is supported by high-quality evidence. For the Tdap vaccine, no evidence of any unexpected harm was found in the meta-analysis of RCTs. Meningococcal vaccines are probably safe during pregnancy, as supported by RCTs comparing meningococcal vaccines to other vaccines. Data supported the safety of hepatitis A and hepatitis B vaccines during pregnancy. In summary, primary and secondary evidence of studies of vaccine components and platforms also used by COVID-19 vaccines supports the safety of COVID-19 vaccines, their components, or their platforms used in other vaccines during pregnancy.

Three recent studies about mRNA-LNP vaccines in pregnant persons, published after this rapid review was finalized, reinforced these findings [75–77]. Shimabukuro et al. published preliminary results from the U.S. surveillance review of the safety of mRNA COVID-19 vaccines during pregnancy [77]. The local and systemic reactions reported were similar among persons who identified as pregnant and non-pregnant persons. Prabhu et al. studied the antibody response of 122 pregnant persons and their neonates at the time of birth who had received one or both doses of an mRNA-based COVID-19 vaccine [75]. COVID-19 vaccination during pregnancy induced a robust maternal immune response, with transplacental antibody transfer detectable as early as 16 days after the first dose. Rottenstreich et al. reported on 20 pregnant persons who received two doses of the SARS-CoV-2 BNT162b2 (Pﬁzer/BioNTech) mRNA vaccine and found a similar antibody response [76]. No safety concern was reported in any of these studies. Also, the proportions of adverse pregnancy and neonatal outcomes among completed pregnancies in the registry were similar to the published incidences in pregnant populations studies before the COVID-19 pandemic [78–84].

This rapid review has several strengths. First, we included reports without time, language, or publication type restriction in humans and animals, to provide a timely answer to a hot topic. Second, we adhered to rigorous recommended quality standards to conduct rapid reviews [11] including independent, data extraction and risk of bias assessment, and a sensitive and comprehensive
search strategy on literature databases to reduce the risk of missing relevant studies. Third, we categorized the exposure to the vaccine components and platforms, which was a challenging issue that frequently demanded exploring additional sources. Finally, we summarized and critically appraised a considerable amount of evidence to conclude if there are safety concerns of the components and platforms, which was a challenging issue that frequently demanded exploring additional sources. Additionally, only 76% of included studies allowed comparisons between vaccinated and unvaccinated pregnant persons, and only five of them were RCTs. Therefore, most of this evidence is observational. Nevertheless, our search strategy did not include the term “Tdap”. Nevertheless, any aluminum adjuvant retrieved by our search strategy was included and reported.

Our study is not exempt from limitations. Twenty-four percent of the included studies were reported as abstracts. Only 11% of the total body of evidence comes from LMICs, limiting the generalizability to these settings. Additionally, only 76% of included studies allowed comparisons between vaccinated and unvaccinated pregnant persons, and only five of them were RCTs. Therefore, most of this evidence is observational. Nevertheless, the absence of safety concerns regardless of the study design and publication type suggest that this could not be a major limitation. Adverse events were reported by the classification used by authors of the original studies; however, we plan to analyze them in the ongoing full review accordingly to our protocol.

Moreover, the set of non-controlled studies do not show unexpected figures with respect to the incidences published in the peer-reviewed literature of neonatal or obstetric outcomes [77]. Regardless of the exposure, all reported rates of spontaneous abortion in exposed pregnant persons, described in Table 2, are below the reported rates of stillbirth for high-income countries: approximately 2–4% of live births [79–83]. Regarding fetal death, rates line with the reported rate in the general population of approximately 3 deaths per 1000 live births [84]. None of the included studies conducted in LMICs reported stillbirth rates, which have been reported to be higher than in HIC: approximately 21 deaths per 1000 live births in low-income countries [84]. We are aware that the list of Tdap vaccines included in our review is incomplete due to the focus of our research question. This vaccine contains aluminum phosphate as an adjuvant, which is not used for the COVID-19 vaccines under study, like the alhydrogel adjuvant. Therefore, our search strategy did not include the term “Tdap”. Nevertheless, any aluminum adjuvant retrieved by our search strategy was included and reported.

The nature of this rapid review did not allow us to search in FDA, the EMA websites, and clinical trials registers, or to contact authors and experts in the field to obtain additional data. For the...
Based on existing data, it seems that there are no evident safety risks of COVID-19 vaccines, their components, or the technological platforms used for pregnant persons. It is reasonable to consider COVID-19 vaccination in pregnant persons because of their higher risk of adverse outcomes. The next full review phase will add more robust evidence on this critical public health issue.

Future experimental data will be needed to assess the pregnancy-related maternal and neonatal COVID-19 vaccine safety. Good quality safety registries, ideally with active surveillance, would also provide extremely useful evidence from real-world data.

### Financial support

This work was supported, in whole, by the Bill & Melinda Gates Foundation [INV008443]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The sponsors had no role in conducting the present study.

### Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Buekens Pierre M. reports financial support was provided by Bill & Melinda Gates Foundation.
Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2021.08.034.

References
[1] Thex L. Access to COVID-19 vaccines: looking beyond COVAX. Lancet 2021;397:941.
[2] Eclercost-Turner M, Upton H. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Acelerator and the COVAX Facility. Milbank Q. 2021.
[3] Herzog LM, Norheim OF, Emanuel EJ, McCoy MS. Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access. BMJ 2021;372:n4853.
[4] Gray KJ, Bortd EA, Atyeo C, Deriso E, Akinnwunmi B, Young N, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. medRxiv 2020;7:2106-18.
[5] Alloitey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m31320.
[6] Figueiro-Filho EA, Yudin M, Farine D. COVID-19 during pregnancy: an overview of maternal characteristics, clinical symptoms, maternal and neonatal outcomes of 10,996 cases described in 15 countries. J Perinat Med 2020;48:900–11.
[7] Vergara-Merino L, Meza N, Couve-Pérez C, Carrasco C, Ortiz-Muñoz L, Madrid E, et al. Maternal and perinatal outcomes related to COVID-19 and pregnancy: An overview of systematic reviews. Acta Obstet Gynecol Scand 2021;100:1279–88.
[8] Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Mortal Virtual Wkly Rep 2020;69(44):1641–7.
[9] Ciapponi A, Bardach A, Comandé D, Berrueta M, Argento FJ, Rodriguez Cairoli F, Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Maternal and perinatal outcomes of pregnant women with COVID-19: findings of a systematic review and meta-analysis. Eur J Epidemiol 2020;35:1003–10.
[10] Kohl KS, Bonhoeffer J, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Vaccine 2021;39:2053974.
[11] Higgins J, Thomas J, Chandler J, MS C, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). In: Cochrane, editor. Cochrane, 2019.
[12] Garrity C, Gartlehner G, Nussbaum-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol 2021;130:13–22.
[13] Page MJ, McKenzie JE, Bossuyt PM, Bouton J, Hoffmann TC, Mulrow CD, et al. The PRISMA statement: an update of guideline for reporting systematic reviews. PLoS Med 2011;8:1000383.
[14] Kohl KS, Bichsel J, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf 2003;12:345–40.
[15] CBER-FDA. In: Services USDofH, Administration F-Fad, Research C-Cibeas, editors. Guidance for Industry - Toxicity Grading Scale or Healthy Adult and Adolescent-Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007.
[16] EMA. ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting EMA - European Medical Agency; 1995.
[17] Benitez Gabriela, Kharbanda Elyse O, et al. Uptake and safety of hepatitis B vaccination during pregnancy: a Vaccine Safety Datalink study. Vaccine 2018;36(41):6111–6.
[18] Källén B, Glaumann PO. Vaccination against H1N1 influenza with Pandemix® during pregnancy and delivery outcome: A Swedish register study. BJOG: Int J Obstet Gynaecol 2012;119:1583–90.
[19] Katz N, Neryo S, Carrega MEP, Del Valle Juarez M, Rancaño C, Pasinovich M, et al. Maternal immunization in argentina: The importance of a safety profile analysis. Open Forum. Infect Dis 2016;3.
[20] Kellner T, Youhanna J, Walker R, Erby K, Janssen RS, Safety and immunogenicity of Hepatitis B in pregnancy. Hepatology 2010;52:469A–70A.
[21] Moro Pedro L, Zheteyeva Yenlik, Barash Faith, Lewis Paige, Cano Maria. Immunogenicity of the Haemophilus influenzae type b (Hib) Vaccine in Pregnant Women. Int J Pharmaceut 2010;38:1–6.
[22] Xabier Mimi, et al. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Special Issue: Advancing maternal immunization programs through research in low and medium income countries 2015;33 (47):4688–92.
[23] Chavant F, Ingrand L, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarie L, et al. The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)pdm2009 influenza. Drug Saf 2011;34:455–65.
[24] Fell DB, Sprague AE, Liu N, Yasseen 3rd AS, Wen S-W, Smith G, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. Am J Public Health 2012;102:e33–40.
[25] Solberg M, Grangerolin M, Svanström Henrik, Valenta-Brantner Palle, Hvids Andris. Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010. Vaccine 2011;29(6):1380–4.
[26] Galindo Santana BM, Pelaez Sanchez OR, Galindo Sardina MA, Leon Villafuerte M, Concepcion Diaz D, Estruch Rancano L, et al. Active surveillance of adverse effects of Pandemrix vaccine to prevent influenza A(H1N1) in Cuba Vigilancia activa de eventos adversos a la vacuna Pandemrix para prevenir la influenza A(H1N1) en Cuba 2011:63:231–8.
[27] Glenn Gregory M, Fries Louis F, Smith Gale, Kramersgeloelr E, Lanzoxin Hans, Guere-Xabier Mimi, et al. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Special Issue: Advancing maternal immunization programs through research in low and medium income countries 2015;33 (47):4688–92.
[28] Groom Holly C, Irving Stephanie A, Koppolu Padma, Smith Nina, Vázquez-Benitez Gabriela, Khambada Elyse O, et al. Uptake and safety of Hepatitis B vaccination during pregnancy: a Vaccine Safety Datalink study. Vaccine 2018;36(41):6111–6.
[29] Groom Holly C, Smith Nina, Irving Stephanie A, Koppolu Padma, Vázquez-Benitez Gabriela, Khambada Elyse O, et al. Uptake and safety of hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink Study. Vaccine 2019;37(44):6648–55.
[30] Guo Y, Allen V, Bajjold E, Coleman B, Drews S, Gournk K, et al. Efficacy and safety of pandemic influenza vaccine in pregnancy. Can J Infect Dis Med Microbiol 2010;21:209.
[31] Håberg Sir E, Trogstad Lill, Gunnes Nina, Wilcox Allen J, Gjessing Håkon K, Samuelsenn Sven Ove, et al. Risk of fetal death after pandemic influenza virus vaccination: New evidence or vaccination bias? Vaccine 2010;28(40):5560–7.
[32] Heldens JCM, Pouwels HGW, Derks CG, Van de Zande SMA, Hoeijmakers MJH. The first safe inactivated equine influenza vaccine formulation adapted with ECOM-Matrix that closes the immunity gain. Vaccine 2009;27(24):4550–7.
[33] Jonas F, Peter S, Cecilia L, Sven C, Anders E, Ortvist Å, et al. Maternal vaccination against H1N1 influenza and offspring mortality: Population based cohort study and sibling design. (Online) Open Forum. Infect Dis 2016;3.
[34] Købke H, Bjafeins PO. Vaccination against H1N1 influenza with Pandemix® during pregnancy and delivery outcome: A Swedish register study. BJOG: Int J Obstet Gynaecol 2012;119:1583–90.
[35] Leivo M, Neryo S, Carrega MEP, Del Valle Juarez M, Rancaño C, Pasinovich M, et al. Maternal immunization in argentina: The importance of a safety profile analysis. Open Forum. Infect Dis 2016;3.
[36] Ludvigsson Jonas F, Zuniga Daniela, Mackenzie Sven, Richardo Lorenzi, Ekbom Anders, Ortvist Ake, et al. Influenza H1N1 vaccination and adverse pregnancy outcome. Eur J Epidemiol 2013;28(7):579–88.
[37] Mackenzie Isla S, MacDonald Thomas M, Shark Saad, Dryburgh Moira, Mantay Brian J, McDonnell Patrick, et al. Influenza H1N1 (swine flu) vaccination: a surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. Br J Clin Pharmacol 2012;75:801–11.
[38] Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simoes EA, et al. Effectiveness and safety of a trivalent influenza vaccine in pregnancy. N Engl J Med 2020;383:402–6.
[39] Munoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, et al. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein
Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants. J Infect Dis 2019;220:1802–15.

[50] Nuñez Rojas Y, Orive Rodriguez N, Varona De La Peña F, Bermúdez Velázquez Y, Raad López AF, Muñoz Martínez Y, et al. Vaccination against influenza a H1N1 and the risk of birth defects. VaccinMonitor 2010;19:209.

[51] Oppermann Marc, Fritzsche Juliane, Weber-Schoenendorf Corinna, Kellner-Stanslawski Brigitte, Allgnol Arthur, Meesse Reesheid, et al. (A)H1N1/v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012;30(30):4455–42.

[52] Pasternak B, Svanstrom H, Molgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A/H1N1 vaccine during pregnancy. JAMA J Am Med Assoc 2012:308:165–74.

[53] Ray Joel G, McGeer Allison J, Blake Jennifer, Lebovic Gerald, Smith Graeme N, Yudin Mark H. Peripartum outcomes: non-adjuvanted v. adjuvanted H1N1 vaccination. CMAJ : Can Med Assoc J = journal de l'Association medicale canadienne 2014;137:1–137.

[54] Rega A, Moore H, De Klerk N, Effer P. Maternal vaccinations in Australia-uptake, safety and impact. Aust N Z J Obstet Gynaecol 2016;56:13–4.

[55] Sammon C, McGrogan A, Snowball J, De Vries CS. Swine flu vaccination in pregnancy and associated miscarriage risk. Pharmacoepidemiol Drug Saf 2011;20:558–9.

[56] Sammon C, Snowball J, McGrogan A, de Vries CS. Evaluating the Hazard of Foetal Death following H1N1 Influenza Vaccination; A Population Based Cohort Study in the UK GPRD. PLoS ONE 2012;7.

[57] Steedman A, Wright D, Schuerer PJW, Clark MHA, Hill AVS, Gilbert SC, et al. Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. npj Vaccines 2019;4.

[58] Tavares Fernanda, Nazareth Irwin, Monegal Javier Sawchik, Kolte Ida, Verstraeten Thomas, Bauchau Vincent. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine 2011;29(17):5835–58.

[59] COVID-19 vaccine tracker. Vaccine Centre at the London School of Hygiene & Tropical Medicine; 2021. https://www.lshtm.shanyapps.io/covid19_vaccine_landscape/ Accessed May 20th 2021.

[60] A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19); 2021. https://clinicaltrialsregister.eu/ctr-search/trial/2021-000893-27/BE.

[61] Study to detect transfer of SARS-CoV-2 antibodies in breastfeeding; 2021. https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000893-27/BE.

[62] Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 2015;60:e11–9.

[63] Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2018;2:CD001269.

[64] Fell DB, Plant RW, Lanes A, Wilson K, Kaufman JS, Basso O, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG 2015;122(1):17–26.

[65] Giles Michelle L, Krishnawamy Sushena, Macartney Kristine, Cheng Allen. The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review. Hum Vaccin Immunother 2019;15(3):687–99.

[66] Jeong S, Jang EJ, Jo J, Jang S. Effects of maternal influenza vaccination on adverse birth outcomes: A systematic review and Bayesian meta-analysis. PLoS ONE 2019;14:e0220910.

[67] Michiels Barbara, Govaerts Frans, Remmen Roy, Vermeire Etiene, Coenen Samuel. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011;29(49):9159–70.

[68] Nunes Marta, Agui Anushka, Omer Saad, Madhi Shabir. The Effects of Influenza Vaccination during Pregnancy on Birth Outcomes: A Systematic Review and Meta-Analysis. Am J Perinatol 2016;33(11):1104–14.

[69] Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME. Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. Obstet Gynecol 2015;126:1075–84.

[70] Zhang Chuan, Wang Xiaodong, Liu Dan, Zhang Lingsi, Sun Xin. A systematic review and meta-analysis of fetal outcomes following the administration of influenza A/H1N1 vaccination during pregnancy. Int J Gynaecol Obstet 2018;141(2):141–50.

[71] Makris Marinos C, Polyzos Konstantinos A, Mavros Michael N, Athanasiou stavros, Rafaelidis Perios I, Falagas Matthew E. Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review. Drug Saf 2012;35(1):1–14.

[72] Nasser R, Rakedson S, Dickstein Y, Moussa A, Solt I, Petersen L, et al. Are all vaccines safe for the pregnant traveller? A systematic review and meta-analysis. J Travel Med 2020;27.

[73] Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D, et al. Antibody response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood. Obstet Gynecol 2021.

[74] Rottenstreicht A, Zaribv C, Oiknine-Djian E, Zigrin R, Wolf DG, Porat S. Efficient maternal-fetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination. Clin Infect Dis 2021.

[75] Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyede T, Panagiotakopoulos L, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med 2021.

[76] Magnus MC, Wilcox AJ, Morken NH, Weinberg CR, Haberg SE. Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. BMJ 2019;364:k3869.

[77] Marden Philip, Smith David W, McDonald Michael J. Congenital anomalies in the newborn infant, including minor variations, a study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin. J Pediatr 1964;64(3):357–71.

[78] Leppig Kathleen A, Weiler Martha M, Cann Cristina L, Cook Catherine A, Holmes Lewis B. Predictive value of minor anomalies. I. Association with major malformations. J Pediatr 1987;110(4):531–7.

[79] Holmes Lewis B. Current concepts in genetics. Congenital malformations. N Engl J Med 1976;295(4):204–7.

[80] Mai Cara T, Ilenberg Jennifer I, Canfield Mark A, Meyer Robert E, Correa Adolfo, Alverston Clinton J, et al. National population-based estimates for major birth defects, 2010–2014. Birth Defects Res 2019;111(18):1420–35.

[81] Feldkamp ML, Carey JC, Byrne JLR, Kruskov S, BOTTO LD. Etiology and clinical presentation of birth defects: population based study. BMJ 2017;357:j2249.

[82] Wang H, Bhutta ZA, Coates MM, Coggeshall M, Dandonia LDK, et al. Global, regional, and, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1725.

[83] WHO. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process; 2021. Accessed 12 May 2021 from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_04May2021.pdf.